Angelini Pharma

“In May, with the help of Blackstone and Italy’s CDP Equity, Angelini Pharma agreed to pay $4.1 billion in cash to buy Catalyst, a premium to its market cap at the time.”

“The deal, which closed in July, catapulted the Italian firm into the United States and the rare-disease market.”

“With $1.5 billion in revenue before the Catalyst deal, Angelini Pharma is the largest piece of the Angelini family’s broader group”

“In 2021, Angelini Pharma bought Swiss biopharma company Arvelle Therapeutics for up to $960 million to get European rights to its anti-seizure drug for epilepsy”

“Then, in May 2025, Angelini acquired the non-U.S. rights for another drug that treats a rare, genetic version of epilepsy from New York City-based Grin Therapeutics for up to $570 million.”

“the group also set up its own small venture fund, seeded with $350 million in capital”

“With three commercial drugs in the market, it also immediately increased Angelini Pharma’s revenue by some $600 million — around 40%.”